Trial Profile
A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2020
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms LUX-Head and Neck-2
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 27 Jul 2020 This trial was completed in United Kingdom according to the European Clinical Trials Database record.
- 06 Jun 2017 Primary (Disease Free Survival (DFS)) endpoint has not been met as per the Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology